- Home
- CASI vs MBRX Comparison
CASI vs MBRX Comparison
Compare CASI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CASI | MBRX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9M | 23.5M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CASI | MBRX |
|---|---|---|
| Price | $0.96 | $7.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $125.00 |
| AVG Volume (30 Days) | 30.5K | ★ 105.9K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $26,846,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.72 | N/A |
| 52 Week Low | $0.93 | $6.01 |
| 52 Week High | $3.97 | $91.25 |
Technical Indicators
Market Signals| Indicator | CASI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 89.96 |
| Support Level | $0.93 | $0.26 |
| Resistance Level | $1.25 | $7.75 |
| Average True Range (ATR) | 0.09 | 0.29 |
| MACD | -0.01 | 0.83 |
| Stochastic Oscillator | 8.91 | 93.19 |
Price Performance
Historical ComparisonAbout CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.